Parkman Healthcare Partners LLC Has $10.03 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Parkman Healthcare Partners LLC raised its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 21.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 532,172 shares of the company's stock after purchasing an additional 93,201 shares during the quarter. Parkman Healthcare Partners LLC owned 0.70% of Nurix Therapeutics worth $10,026,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. The Manufacturers Life Insurance Company lifted its holdings in shares of Nurix Therapeutics by 2.1% in the fourth quarter. The Manufacturers Life Insurance Company now owns 31,025 shares of the company's stock worth $585,000 after buying an additional 642 shares in the last quarter. Corebridge Financial Inc. lifted its holdings in shares of Nurix Therapeutics by 2.3% in the fourth quarter. Corebridge Financial Inc. now owns 34,907 shares of the company's stock worth $658,000 after buying an additional 770 shares in the last quarter. Kennedy Capital Management LLC lifted its holdings in shares of Nurix Therapeutics by 0.7% in the fourth quarter. Kennedy Capital Management LLC now owns 114,623 shares of the company's stock worth $2,159,000 after buying an additional 785 shares in the last quarter. US Bancorp DE raised its stake in Nurix Therapeutics by 144.7% during the fourth quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after purchasing an additional 842 shares in the last quarter. Finally, Summit Investment Advisors Inc. raised its stake in Nurix Therapeutics by 13.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock valued at $138,000 after purchasing an additional 877 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Wells Fargo & Company cut their price objective on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 9th. Stifel Nicolaus dropped their target price on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Stephens reaffirmed an "overweight" rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. HC Wainwright reiterated a "buy" rating and issued a $36.00 price target on shares of Nurix Therapeutics in a report on Wednesday, April 2nd. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $27.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, April 29th. Three research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat.com, Nurix Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $30.44.

Nurix Therapeutics Trading Up 0.4%

Shares of Nurix Therapeutics stock traded up $0.04 during trading hours on Monday, reaching $9.60. The stock had a trading volume of 466,981 shares, compared to its average volume of 876,564. The firm has a 50 day simple moving average of $11.07 and a two-hundred day simple moving average of $16.80. The firm has a market capitalization of $731.48 million, a price-to-earnings ratio of -3.32 and a beta of 2.23. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The firm had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. During the same quarter last year, the firm earned ($0.76) EPS. Sell-side analysts forecast that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,377 shares of the business's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the sale, the insider now owns 61,516 shares in the company, valued at approximately $707,434. The trade was a 5.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Houte Hans Van sold 6,198 shares of Nurix Therapeutics stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $11.33, for a total value of $70,223.34. Following the transaction, the chief financial officer now directly owns 33,724 shares in the company, valued at approximately $382,092.92. This trade represents a 15.53% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 17,838 shares of company stock valued at $221,500. 7.40% of the stock is currently owned by corporate insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.